Plasma levels of galectin-3-binding protein reflect type i interferon activity and are increased in patients with systemic lupus erythematosus

Lupus Science and Medicine

Volumn 1, Issue 1, 2014, Pages

  Nielsen, Christoffer T ^a,b   Lood, Christian ^c   Østergaard, Ole ^a   Iversen, Line V ^a,d   Voss, Anne ^e   Bengtsson, Anders ^c   Jacobsen, Søren ^b   Heegaard, Niels H H ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b University of Copenhagen   (Denmark)

^c LUND UNIVERSITY   (Sweden)

^d BISPEBJERG HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BINDING PROTEIN; GALECTIN 3 BINDING PROTEIN; INTERFERON; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASSAY; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPORTER GENE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

EID: 84941200697     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2014-000026     Document Type: Article

References (39)

1. Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus 2010;19:1012-9.
2. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39.
3. Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301:5-8.
4. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-5.
5. Weckerle CE, Franek BS, Kelly JA, et al. Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum 2011;63:1044-53.
6. Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-71.
7. Bauer JW, Petri M, Batliwalla FM, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study. Arthritis Rheum 2009;60:3098-107.
8. Petri M, Singh S, Tesfasyone H, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009;18:980-9.
9. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
10. Rose T, Grutzkau A, Hirseland H, et al. IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis 2013;72:1639-45.
11. Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011;70:1905-13.
12. Ostergaard O, Nielsen CT, Iversen LV, et al. Unique protein signature of circulating microparticles in systemic lupus erythematosus. Arthritis Rheum 2013;65:2680-90.
13. Ullal AJ, Reich CF III, Clowse M, et al. Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus. J Autoimmun 2011;36:173-80.
14. Beyer C, Pisetsky DS. The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol 2010;6:21-9.
15. Nielsen CT, Ostergaard O, Stener L, et al. Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation. Arthritis Rheum 2012;64:1227-36.
16. Sasaki T, Brakebusch C, Engel J, et al. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J 1998;17:1606-13.
17. Ullrich A, Sures I, D'Egidio M, et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem 1994;269:18401-7.
18. Grassadonia A, Tinari N, Fiorentino B, et al. The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. Endocrinology 2004;145:4728-36.
19. Shaked I, Hanna DB, Gleissner C, et al. Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol 2014;34:1085-92.
20. Cheung KJ, Libbrecht L, Tilleman K, et al. Galectin-3-binding protein: A serological and histological assessment in accordance with hepatitis C-related liver fibrosis. Eur J Gastroenterol Hepatol 2010;22:1066-73.
21. Iacobelli S, Sismondi P, Giai M, et al. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer 1994;69:172-6.
22. Lee YJ, Kang SW, Song JK, et al. Serum galectin-3 and galectin-3 binding protein levels in Behcet's disease and their association with disease activity. Clin Exp Rheumatol 2007;25(4 Suppl 45):S41-5.
23. Ohshima S, Kuchen S, Seemayer CA, et al. Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum 2003;48:2788-95.
24. Tinari N, Natoli C, D'Ostilio N, et al. 90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200×10(6) cells/L. Arch Pathol Lab Med 1998;122:178-81.
25. Zeimet AG, Natoli C, Herold M, et al. Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. Int J Cancer 1996;68:34-8.
26. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
27. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
28. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
29. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
30. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
31. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
32. Nielsen CT, Ostergaard O, Johnsen C, et al. Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus. Arthritis Rheum 2011;63:3067-77.
33. Hermansen ML, Hummelshoj L, Lundsgaard D, et al. Increased serum beta2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus patients. Lupus 2012;21:1098-104.
34. Canosi U, Mascia M, Gazza L, et al. A highly precise reporter gene bioassay for type I interferon. J Immunol Methods 1996;199:69-76.
35. Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70:2029-36.
36. Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005;52:1491-503.
37. Nikpour M, Dempsey AA, Urowitz MB, et al. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythematosus. Ann Rheum Dis 2008;67:1069-75.
38. Kong KO, Tan AW, Thong BY, et al. Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol 2009;156:134-40.
39. Landolt-Marticorena C, Bonventi G, Lubovich A, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009;68:1440-6.